LYNNAE JACKSON

Executive with over thirty years of biotechnology experience managing Phase I through Phase IV Clinical Trials and over 20 years of formal supervisory experience in clinical operations. Persistent leader eager to lead and grow organizations. Skilled in strategic planning, problem-solving, and communication with good understanding of business principles, project management and team leadership. Collaborative with relentless work ethic.

• American Society of Clinical Oncology (ASCO)
• Drug Information Association (DIA)
• Alpha Kappa Alpha Sorority, Inc.

• Oncology: Renal Cell Carcinoma, Bladder Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Non-small cell lung cancer (NSCLC), Pancreatic Cancer and other advanced solid tumors
• Nephrology
• Rheumatology
• Infectious Disease
• Endocrinology: Type 2 Diabetes

• Daniel Peter Petrylak, Raymond P. Perez, Jingsong Zhang, David C. Smith, Joseph D. Ruether, Srikala S. Sridhar, Randeep S. Sangha, Joshua Michael Lang, Elisabeth I. Heath, Jaime R. Merchan, Elaina M. Gartner, Rong Chu, Banmeet Anand, Fernando Donate, Lynnae Jackson, Jeffrey Adams, Amal Melhem-Bertrandt, Jonathan E. Rosenberg. A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer. J Clin Oncol 35:15, 2017 suppl, 106-106
• Jonathan E. Rosenberg, Elisabeth I. Heath, Peter J. Van Veldhuizen, Jaime R. Merchan, Joshua Michael Lang, Joseph D. Ruether, Daniel Peter Petrylak, Randeep S. Sangha, David C. Smith, Srikala S. Sridhar, Elaina M. Gartner, Martha Vincent, Rong Chu, Banmeet Anand, Fernando Donate, Lynnae Jackson, Leonard M. Reyno, and Jingsong Zhang. Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). J Clin Oncol 34, 2016 (suppl; abstr 4533)
• Daniel Peter Petrylak, Elisabeth I. Heath, Guru Sonpavde, Saby George, Alicia Katherine Morgans, Bernhard J. Eigl, Joel Picus, Susanna Y. Cheng, Sebastien J. Hotte, Elaina M. Gartner, Martha Vincent, Rong Chu, Banmeet Anand, Karen Morrison, Lynnae Jackson, Leonard M. Reyno, Evan Y. Yu. Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). J Clin Oncol 34, 2016 (suppl; abstr 4532)
• Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul;24(7):1792-801.
• DK Armstrong, PJ Sabbatini, TJ Herzog, M Vincent, LS Jackson, and L Reyno. Phase I Study of AGS-8M4, an anti-AGS-8 human antibody, in advanced Ovarian cancer. 2010 ASCO Annual Meeting Poster Presentation.
• Hidalgo M., O'Reilly EM, Ko Y.J., Blaszkowsky LS, Rarick MU, Rocha Lima CMS, Ritch PS, Chan E., Spratlin JL, Macarulla T, McWhirter E, Pezet d., Lichinister M, Roman LD, Hartford A., Jackson L., Vincent M, Reyno LM, and Wolpin BM. Improved 6-Month Survival Rate in Subjects with Prostate Stem Cell Antigen Positive Tumors in a Global, Randomized Phase 2 Trial Comparing Gemcitabine vs. Gemcitabine + AGS-1C4D4 (ASP6182) in Metastatic Pancreatic Cancer. 13th World Congress on Gastrointestinal Cancer, 2011; Oral Presentation.
• Wolpin BM., O'Reilly EM, Ko Y.J., Blaszkowsky LS, Rarick MU, Rocha Lima CMS, Ritch PS, Chan E., Spratlin JL, Macarulla T, McWhirter E, Pezet d., Lichinister M, Roman LD, Hartford A., Jackson L., Vincent M, Reyno LM, and Hidalgo M. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). Journal of Clinical Oncology, 2011: Vol 29, Issue 15S, page 263s.
• Armstrong DK, Herzog TJ, Reyno LM, Vincent M., Jackson L., Sabbatini P. A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer. Journal of Clinical Oncology, 2010. Vol 28, No. 15S, page 404s.
• Hertel J., Locay H., Scarlata D., Jackson L., Prathakanti R., and Audhya P., Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease (CKD) converting from once-weekly recombinant human erythropoietin (rHuEPO): Results from Simplify the Treatment of Anemia with Aranesp (STAAR) study. American Journal of Nephrology, 2006; 26:149-156.
• Brophy G., Sheehan V., Romig B., Voss G., Jackson L., Scarlata D., and Audhya P., Utilization patterns of erythropoiesis-stimulating proteins (ESPs) in anemic, critically ill patients admitted to the intensive care unit (ICU): interim results from the ASSESS study. Accepted as a poster presentation at the 2006 SCCM Conference in San Francisco, CA.
• Brophy G., Sheehan V., Romig B., Voss G., Jackson L., Scarlata D., and Audhya P., Utilization patterns of erythropoiesis-stimulating proteins (ESPs) in anemic, critically ill patients admitted to the intensive care unit (ICU): interim results from the ASSESS study. Accepted as a poster presentation at the 2005 ASHP Conference in Las Vegas, NV.
• Hertel J., Locay H., Scarlata D. and Jackson L., Darbepoetin Alfa maintains mean Hemoglobin (Hgb) levels in Chronic Kidney Disease (CKD) patients who are Erythropoietin(EPO) naïve or converting from EPO therapy. Accepted as a poster presentation at the 2004 NKF Conference in Chicago, IL.
• Shikiar R., Rentz A., and Jackson L., Assessment of a Novel Method of Subcutaneous Injection in Rheumatoid Arthritis (RA) Patients: Patient Preferences at End of Trial. Accepted as an oral presentation at the 2003 ACR/AHRP Conference in Orlando, Florida.
• Suranyi M., Walker R., Jackson L., Feaster J., and McDermott-Vitak A. Darbepoetin Alfa Administered Once Every Other Week Corrects Anemia in Patients with Chronic Kidney Disease (CKD). Accepted as a poster presentation at the 2001 ASN Conference in San Francisco.
• Suranyi M., Walker R., Jackson L., Feaster J., and McDermott-Vitak A. Aranesp (Darbepoetin Alfa) Administered Once Every Other Week Corrects Anaemia in Patients with Early Chronic Kidney Disease (CKD). Accepted as a poster presentation at the Australia and New Zealand Society of Nephrology Conference, 2001.
• Suranyi M., Jackson L., Lubina J., and McDermott A. A Novel Erythropoiesis Stimulating Protein (NESP) Administered Once Every Other Week Corrects Anemia in Patients with Chronic Renal Insufficiency (CRI). Accepted as a poster presentation at the ERA-EDTA Congress in Vienna, 2001.
• Suranyi M., Jackson L., Lubina J., and McDermott A. A Novel Erythropoiesis Stimulating Protein (NESP) Administered Once Every Other Week Corrects Anemia in Patients with Chronic Renal Insufficiency (CRI). Accepted as a poster presentation at the NKF Clinical Meeting in Orlando, FL, 2001.
• Lee P., Pivarnik J., Bukar J., rhIGF-I Clinical Investigators, and Jackson L. et. al.A Randomized, Placebo-Controlled Trial of combined Insulin-Like Growth Factor-I and Low-Dose Growth Hormone Therapy for Wasting Associated with HIV Infection. Journal of Clinical Endocrinology and Metabolism, 1996
• Jackson L.S., Bukar J.G., Gesundheit N., and Deasy C. A Comparison of the Quality of Life of HIV Positive Patients and Healthy Controls. Poster presentation at the 10th International Conference on AIDS, 1994 in Yokohama, Japan.
• Bukar J.G., Jackson L., Muro J., Jenks B.H., et. al. Effect of a Combination of Growth Hormone and rhIGF-I on the Appetite of HIV-I Positive Patients with Weight Loss. Poster presentation at the 10th International Conference on AIDS, 1994 Yokohama, Japan